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ABSTRACT
Background
Envenoming resulting from snakebites is an important public health problem in many
tropical and subtropical countries. Few attempts have been made to quantify the burden, and
recent estimates all suffer from the lack of an objective and reproducible methodology. In an
attempt to provide an accurate, up-to-date estimate of the scale of the global problem, we
developed a new method to estimate the disease burden due to snakebites.
Methods and Findings
The global estimates were based on regional estimates that were, in turn, derived from data
available for countries within a defined region. Three main strategies were used to obtain
primary data: electronic searching for publications on snakebite, extraction of relevant country-
specific mortality data from databases maintained by United Nations organizations, and
identification of grey literature by discussion with key informants. Countries were grouped into
21 distinct geographic regions that are as epidemiologically homogenous as possible, in line
with the Global Burden of Disease 2005 study (Global Burden Project of the World Bank).
Incidence rates for envenoming were extracted from publications and used to estimate the
number of envenomings for individual countries; if no data were available for a particular
country, the lowest incidence rate within a neighbouring country was used. Where death
registration data were reliable, reported deaths from snakebite were used; in other countries,
deaths were estimated on the basis of observed mortality rates and the at-risk population. We
estimate that, globally, at least 421,000 envenomings and 20,000 deaths occur each year due to
snakebite. These figures may be as high as 1,841,000 envenomings and 94,000 deaths. Based
on the fact that envenoming occurs in about one in every four snakebites, between 1.2 million
and 5.5 million snakebites could occur annually.
Conclusions
Snakebites cause considerable morbidity and mortality worldwide. The highest burden exists
in South Asia, Southeast Asia, and sub-Saharan Africa.
The Editors’ Summary of this article follows the references.
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Venomous snakes are found throughout most of the world
(including many oceans), except for a few islands, frozen
environments, and high altitudes [1]. Envenomings and deaths
resultingfromsnakebites,however,areaparticularlyimportant
public health problem in the rural tropics. Populations in these
regions experience high morbidity and mortality because of
poor access to health services, which are often suboptimal, and,
in some instances, a scarcity of antivenom, which is the only
speciﬁc treatment. A large number of victims survive with
permanentphysicalsequelaeduetolocaltissuenecrosisand,no
doubt, psychological sequelae. Because most snakebite victims
are young [2], the economic impact of their disability is
considerable. Despite the scale of its effects on populations,
snakebite has not received the attention it deserves from
nationalandinternationalhealthauthorities,andmaytherefore
be appropriately categorized as a neglected tropical disease.
Few reliable incidence data are available from the rural
tropics where snakebites occur most commonly; reliable data
are mostly limited to a few developed countries where bites
are rare. Thus, the true global incidence of snakebite
envenoming, its impact, and characteristics in different
regions remain largely unknown. However, information on
the number of bites, envenomings, and deaths and on the
frequency of long-term sequelae due to snakebites are
essential for assessing the magnitude of the problem, drawing
up guidelines for management, planning health care resour-
ces (particularly antivenom), and training medical staff to
treat snakebites.
Recent estimates, which are fragmentary, variously suggest
that worldwide, venomous snakes cause ‘‘5.4 million bites,
about 2.5 million envenomings and over 125,000 deaths
annually’’ [3], ‘‘more than 3 million bites per year resulting in
more than 150,000 deaths’’ [4], or ‘‘several million bites and
envenomings annually with tens of thousands of deaths’’ [5].
Since the reviews by Swaroop and Grab in 1954 [6] and
Chippaux in 1998 [3], and a global overview of bites and stings
from venomous animals by White [4], no comprehensive global
assessment has been made of snakebite epidemiology. Swaroop
and Grab’s review was based mainly on hospital admissions [6],
and such data from the rural tropics are fraught with
inaccuracies. For example, many snakebite victims in these
areas are not hospitalized and seek traditional treatments [7].
Hospital mortality data are well known to underestimate
overall mortality due to snakebites [8]. Chippaux [3] and White
[4] do not give any details of the methodology used to calculate
their estimates. For these reasons, re-estimating the global
burden of snakebite using scientiﬁcally rigorous, replicable
methodologies was necessary.
Theobjectiveofthisarticleistoreviewthecurrentlyavailable
literature on snakebite worldwide, and to attempt to make
scientiﬁcally robust estimates of the current burden. Toward
that end, we developed a method to obtain global estimates of
envenominganddeathsduetosnakebites;theseglobalestimates
were based on regional estimates, which were, in turn, derived
from data available for countries within a deﬁned region.
Methods
The methodology consisted of two components, data
retrieval and estimation.
Data Retrieval
The data retrieval process consisted of three main
strategies: electronic searching for publications on snakebite;
extraction of relevant country speciﬁc data required for
estimation from databases maintained by the World Health
Organization (WHO), United Nations (UN), World Bank
(WB), and Food and Agriculture Organization (FAO); and
identiﬁcation of grey literature by discussion with key
informants.
Publications on snakebite. The keywords used for this
search were ‘‘snakebite and epidemiology,’’ ‘‘snakebite and
incidence,’’ ‘‘snakebite and morbidity,’’ ‘‘snakebite and
mortality,’’ ‘‘snakebite and envenomation,’’ ‘‘snakebite and
envenoming,’’ and ‘‘snakebite and deaths.’’ The languages of
publications included English, French, and Spanish. The
process of the published literature review is shown in Figure
1. The original search, carried out at the Liverpool School of
Tropical Medicine by a professional data retriever, generated
3,256 citations of publications relating to snakebite. The
abstracts of these citations were downloaded and scrutinized
by a snakebite expert (DGL) to select all the publications that
were likely to be useful for the purpose of the study,
considering its objectives. This step resulted in retrieval of
272 full papers. These papers were scrutinized by three
independent researchers at the University of Kelaniya to
select publications that contained information that would be
useful for estimation of incidence and mortality rates of
snakebite. Papers reporting extremely high rates from very
small studies were not included because they were considered
unreliable. This resulted in short-listing 158 original papers
and two books.
The data were extracted from the publications, transcribed
Figure 1. Schematic Diagram of the Steps of the Literature Review
doi:10.1371/journal.pmed.0050218.g001
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Microsoft Excel by one researcher. Data from work done
earlier than 1985 were excluded from this database. The main
variables extracted were: the number of snakebites estimated
or reported for a country, nationally, or subnationally; the
incidence rate of snakebite; the number of deaths due to
snakebite estimated or reported for the entire country; the
mortality rate of snakebite; and the percentage of venomous
bites out of all snakebites where available. This database was
independently cross-checked with the original publications
for accuracy and completeness by two other researchers.
When more than one value was available for the same
country from a number of sources, only the lowest and the
highest values were used. When different rates were quoted in
the same publication, the lowest and the highest rates were
used. Data for calculation of the number of snakebite
envenomings were obtained for 46 countries [9–60] while
data for calculation of the number of deaths due to snakebite
were obtained for 22 countries [9–11,18, 31,47,49,51,56,58–72]
by this process.
Databases reviewed. The WHO Headquarters in Geneva,
Switzerland, permitted us access to the WHO mortality
database [73] and the WHO population database [74]. The
absolute annual number of deaths due to snakebite reported
for each country was obtained for the period 1985–2006 from
the WHO mortality database [73]. Both versions 9 and 10 of
the International Statistical Classiﬁcation of Diseases and
Health Problems (ICD) [75,76] had been used during this
period by the reporting countries. The main codes for
snakebites under the two versions are ICD-E905.0 (venomous
snakes and lizards as the cause of poisoning and toxic
reactions) where ICD9 is used, and ICD–T-63.0 (toxic effect of
contact with snake venom) in situations where ICD10 is used.
We were concerned only with snakebite mortality, which the
WHO mortality database tabulates under code X20 (deaths
due to venomous snakes and lizards) and not under E and T
codes. Thus the data we report for the countries where we
obtained information from the WHO mortality database have
been tabulated under ICD10 code X20. Annual population
estimates by country were obtained from the WHO pop-
ulation database for the 22-y period 1985–2007. For UN
countries that are not members of the WHO, the estimates
were obtained from the FAO database [77] and UN
population database [78]. For each country, the Human
Development Index (HDI) for 2005 was obtained from the
United Nations Development Programme (UNDP) database
[79] and the percentage coverage of vital registration of
deaths was obtained from the World Health Statistics Report
2007 [80]. The population living in rural areas for each
country reported every 5 y from 1985 to 2005 was extracted
from the FAO database [77]. All the variables were double
entered and checked.
Search for grey literature. Regional Ofﬁces and several
country ofﬁces of the WHO were contacted to request
information on incidence and mortality of snakebite. After
the primary review of literature, the countries that did not
have reliable published data on snakebite were identiﬁed. We
contacted Ministries of Health, National Poison Centres,
researchers, and experts on snakebite in these countries for
information on the incidence of, and mortality due to,
snakebite in their countries.
A second search on the internet using the Google search
engine was conducted for all countries still without data. The
keywords used for this search were the ‘‘(country name) and
snakebite.’’ This search included sources in English, Japanese,
and Russian.
Estimation
Two hundred twenty-seven countries were grouped into 21
distinct geographical regions in this study, according to the
classiﬁcation used for the Global Burden of Disease (GBD)
2005 study (Global Burden Project of the World Bank) [81].
This latest iteration of the GBD study is led by the new
Institute for Health Metrics and Evaluation at the University
of Washington, with key collaborating institutions including
Harvard University, WHO, Johns Hopkins University, and the
University of Queensland, and is funded by the Bill and
Melinda Gates Foundation. The 21 regions have been deﬁned
with two objectives: ﬁrst, to deﬁne regions that are as
epidemiologically homogeneous as possible, so that informa-
tion from detailed studies in one country can plausibly be
extrapolated to other countries in the region; and second,
related to the ﬁrst, to create burden estimates that are useful
to individual countries in planning for health sector
activities. The regions were chosen using mortality estimates
from the WHO and UN, in addition to what is known about
country-speciﬁc epidemiological conditions. The 21-region
classiﬁcation was adopted because this study also has the
same objectives, albeit in relation to a single disease
condition (snakebite envenoming), and for the sake of
consistency with the GBD methodology. The 227 countries
were listed and categorized into two groups, i.e., countries in
which snakebite occurs and countries in which snakebite does
not occur. This categorization was done by content experts,
based on the availability of evidence to support the
occurrence of recent snakebite in each country.
Assumptions. A country was considered free of snakebites
(and associated mortality) if no literature (published or
unpublished) indicated the occurrence of snakebite since
1985. A country was considered to have no mortality due to
snakebites, even though snakebites have been reported, if no
mortality statistics have been reported to the WHO mortality
database from 1990 to date, provided that the country has a
HDI 0.750 or higher and vital registration coverage of deaths
75% or higher. The most recent incidence or mortality rate
that had been calculated after 1985 was assumed to be the
current rate for a country. If the HDI was 0.750 or higher and
coverage of vital registration of deaths was 75% or higher, the
average number of deaths reported over the last 5 y to the
WHO mortality database in the respective category of the
ICD code was assumed to be the total number of deaths due
to snakebite for the country.
The assumptions made on the representativeness of data
were based on the national coverage of the data. It was
assumed that the different types of data (data originating
from different sources) were representative in the following
order of priority. (1) Published community-based national
data; (2) published hospital-based national data; (3) unpub-
lished national data (community/hospital based); (4) pub-
lished community-based subnational data; (5) unpublished
community based subnational data; and (6) published subna-
tional hospital data where the population served was known.
High and low estimates of the number of envenomings and
deaths due to snakebite for each GBD region were derived
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ings and deaths for countries within a region. Regional
estimates were summed up to arrive at global estimates.
Calculation and estimation of the incidence rates and
number of snakebite envenomings (Figure 2). Four types of
data were available to be used for calculation of the incidence
rate of snakebite envenoming (per 100,000 population) for
each country. These data were prioritised as follows. (1)
Published data or estimates of the absolute number of annual
snakebites in a country and the number of persons seeking
treatment for snakebite each year, reported by National
Ministries of Health, National Poison Centres, or the entire
hospital system in a country;(2) unpublished data or estimates
of the absolute number of annual snakebites in a country and
the number of persons seeking treatment for snakebite each
year, reported by National Ministries of Health, National
Poison Centres, or the entire hospital system in a country; (3)
number of snakebites based on the incidence reported in
published community-based studies at the subnational level;
and (4) number of snakebites based on the incidence reported
in published hospital-based studies at the subnational level.
Incidence rates calculated from nationwide community-
based studies were not available in the literature. Where the
absolute annual number of envenomings for a given country
was available, the incidence rate was calculated using the
country population for the reporting year as the denomi-
nator. For subnational data, the incidence rate was calculated
using the population surveyed or the population served by
the hospitals, as the denominator.
The following steps were then followed. For countries
where snakebites do not occur, a zero incidence was used. For
countries having a single national incidence rate, the rate was
applied to the total population to estimate the number of
snakebites for the country. For countries having a single
subnational incidence rate, the rate was applied to the
subnational study population, and the number obtained was
considered the number of snakebites for the entire country.
Two incidence rates (high and low) were calculated for
countries for which more than one rate was available. The
lower rate was applied to the total population of the country
for the low estimate. The high estimate was obtained by
summing the estimates obtained after applying the higher
incidence rate to the rural population and the lower rate to
the urban population of that country.
For countries where snakebite is known to occur, but which
did not have data, two estimates of the number of snakebites
occurring within the country were calculated as follows. The
low estimate was calculated by applying the lowest incidence
rate reported by another country within the same GBD 2005
region to the given country’s population. The high estimate
was calculated by summing the estimates obtained after
applying the highest incidence rate reported within the same
GBD 2005 region to the given country’s rural population and
the lowest incidence rate reported within the same region to
the given country’s urban population.
Calculation and estimation of mortality rates and number
of deaths due to snakebites (Figure 3). For countries where
snakebites do not occur the number of deaths due to
snakebites was estimated as zero. For countries that had a
HDI of 0.750 or more in 2005 [79], and the rate of vital
Figure 2. Algorithm for Calculation of Morbidity Due to Snakebite
doi:10.1371/journal.pmed.0050218.g002
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reporting [80], the average of the number of deaths reported
annually for the latest 5 y was estimated to be the number of
deaths for 2007. For countries that had a HDI below 0.750 or
a vital registration rate below 75%, the absolute number of
deaths due to snakebite was calculated based on literature
and other sources of information. The cut-off points for HDI
and percentage vital registration of deaths were set at 0.750
and 75%, respectively, being the upper limit of the
interquartile range
The following steps were used in the estimation of deaths
due to snakebites. Mortality rates (per 100,000 population)
were calculated using the country populations of the
reporting year as the denominator. If only one mortality
rate was available, it was considered the lower mortality rate.
If more than one mortality rate was available for the same
country, the lowest and the highest reported rates were
considered the low and high mortality rates. For subnational
data, the mortality rate was calculated using the population
surveyed, or the population served by the hospitals, as the
denominator. Within each GBD 2005 region the lowest and
the highest mortality rates reported were applied to countries
without data.
The following method was used for estimation of the
number of deaths due to snakebite for each country. For
countries where snakebites do not occur, zero mortality was
used. For countries having national mortality rates, the rate
was applied to the total population of that country to arrive
at the estimate of the number of deaths due to snakebites. For
countries having subnational mortality rates, the higher
mortality rate was applied to the rural population of that
country and the lower mortality rate was applied to the urban
population of that country, and the two estimates were
summed to arrive at the high estimate for that country.
Estimation of total snakebite burden. The majority (70%)
of the published papers on snakebite described only snake-
bite envenomings, while a very few (n ¼ 14) described both
total snakebite and snakebite resulting in envenoming. A
considerable number (n ¼ 32) did not make a distinction
between bites resulting in envenoming and bites not resulting
in envenoming. Although our prime estimate was snakebite
envenomings, we also estimated the total number of snake-
Figure 3. Algorithm for Calculation of Mortality Due to Snakebite
doi:10.1371/journal.pmed.0050218.g003
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envenoming out of total bites reported in a few publications.
The calculated number of bites without envenoming was
added to the number of bites with envenoming estimated
originally.
Results
The review of published literature generated 3,256 cita-
tions on snakebite. Data on incidence and/or mortality of
snakebite were available in 160 publications.
Estimation of Incidence Rate and the Number of
Snakebite Envenomings
Of the 227 countries, 58 were identiﬁed as countries where
venomous snakebites do not occur. Data useful for calcu-
lation of the incidence of snakebite in 62 countries were
found in 40 publications [9–60]. The review of grey literature
resulted in two Web sources [82,83] and 13 communications
that generated data for 15 more countries. Data thus
obtained for 77 countries were used for the estimation of
the number of snakebite envenomings in 92 countries
without data (Figure 4; Table S1). The estimated number of
snakebite envenomings by region is shown in Figure 5 and
Table 1. In our most conservative estimate, the highest
number of envenomings were estimated for South Asia
(121,000) followed by Southeast Asia (111,000), and East
Sub-Saharan Africa (43,000). The lowest numbers were
estimated for Central Europe and Central Asia. We estimate
that, globally, at least 421,000 envenomings occur annually;
this ﬁgure may be as high as 1,841,000. According to our most
conservative country estimates, which were used to calculate
the regional estimates, India had the most envenomings at
81,000 per year. Sri Lanka (33,000), Viet Nam (30,000), Brazil
(30,000), Mexico (28,000), and Nepal (20,000) were the other
countries that had a high estimated number of envenomings
annually.
Estimation of Mortality Rate and Number of Deaths Due
to Snakebites
Seventy-four countries had a HDI 0.750 or higher [79] and
a death registration rate 75% or higher [80]. Of these, 15
countries were classiﬁed as not having snakebites. Among the
rest, 27 countries had no deaths due to snakebite according to
the WHO mortality database [73]. The other 32 countries
reported deaths due to snakebite, which were used for
calculation of the country-speciﬁc mortality rates. Among
countries with a lower HDI or a lower rate of registration,
mortality rates were obtained from published literature for
23 countries [9–11,18,31,47,49,51, 56,58–72]. Grey literature
provided mortality rates for 22 more countries. When the
Figure 4. Countries with Data on Snakebite Envenoming
doi:10.1371/journal.pmed.0050218.g004
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Global Burden of SnakebiteFigure 5. Regional Estimates of Envenomings Due to Snakebite (Low Estimate)
doi:10.1371/journal.pmed.0050218.g005
Table 1. Global Estimates of the Snakebite Envenomings in 2007 by Region
Region Snakebite Envenomings per Year Range for Wider Region
Low Estimate Incidence/100,000 High Estimate Incidence/100,000
Asia Pacific, high income 703 0.39 3,156 1.74 237,379–1,184,550
Asia, Central 228 0.29 1,213 1.55
Asia, East 4,582 0.33 218,673 15.73
Asia, South 121,333 7.84 463,350 29.94
Asia, Southeast 110,533 18.82 498,158 84.65
Australasia 1,099 4.41 1,260 5.06 1,099–1,260
Caribbean 1,098 2.82 8,039 20.66 1,098–8,039
Europe, Central 106 0.09 2,489 2.09 3,961–9,902
Europe, Eastern 795 0.38 795 0.38
Europe, Western 3,060 0.74 6,618 1.61
Latin America, Andean 6,548 12.90 27,653 54.47 80,329–129,084
Latin America, Central 42,087 19.04 67,373 30.47
Latin America, Southern 2,058 3.46 2,163 3.63
Latin America, Tropical 29,636 14.97 31,895 16.12
North Africa/Middle East 3,017 0.71 80,191 18.88 3,017–80,191
North America, high income 2,683 0.79 3,858 1.14 2,683–3,858
Oceania 361 3.87 4,635 49.70 361–4,635
Sub-Saharan Africa, Central 18,176 20.28 47,820 53.37 90,622–419,639
Sub-Saharan Africa, East 42,834 12.94 74,823 22.61
Sub-Saharan Africa, Southern 1,613 2.34 2,296 3.33
Sub-Saharan Africa, West 27,999 8.87 294,700 93.34
Total 420,549 6.28 1,841,158 27.5 420,549–1,841 158
doi:10.1371/journal.pmed.0050218.t001
PLoS Medicine | www.plosmedicine.org November 2008 | Volume 5 | Issue 11 | e218 1597
Global Burden of Snakebiteother 43 countries without snakebites were excluded, no
snakebite mortality data existed for 65 countries. The
number of deaths due to snakebite in these 65 countries
was estimated based on the 104 countries for which mortality
data were available (Figure 6; Table S2). The estimated
number of snakebite deaths by region are shown in Table 2
and Figure 7. In our most conservative estimate the highest
number of deaths due to snakebite was estimated in South
Asia (14,000) followed by West sub-Saharan Africa (1,500) and
East sub-Saharan Africa (1,400). The lowest numbers of
deaths were estimated for Australasia, Southern Latin
America, and Western Europe. We estimate that globally, at
least 20,000 deaths occur from snakebite annually; this ﬁgure
may be as high as 94,000. According to our most conservative
country estimates that were used to calculate the regional
estimates, India had the highest number of deaths due to
snakebite in the world with nearly 11,000 deaths annually.
Bangladesh and Pakistan had over 1,000 deaths per year.
Estimation of the Total Number of Snakebites
(Envenomed and Nonenvenomed Bites)
Even bites by nonvenomous snakes or bites by a venomous
snake that do not cause envenoming may pose a burden on
health systems, because in some regions victims access the
health care system and require assessment. We tried to
estimate the total number of snakebites (envenomed and
nonenvenomed) by looking at the literature in different
continents to enable us to extrapolate from the number of
envenomings. In Asia, various studies suggest that envenomed
bites constitute between 12% and 50% of the total number of
bites [17,84,85]. The most complete data suggest that
envenomed bites constitute 18% and 30% of the total in
India and Pakistan, respectively (Ian Simpson, personal
communication). Data are limited for North and Latin
America: in Brazil, 56% of the snakebites were caused by
nonvenomous snakes [86], and American Association of
Poison Control Centers data suggest that the total number
of snakebites is about three times that of venomous bites [37].
African data are equally variable; 19% of snakebite victims in
Kenya were bitten by potentially venomous snakes [7], and
two studies in West Africa suggested that envenoming made
up 45% and 87% of total bites [60,87].
These data indicate that the relationship of the total
number of snakebites to envenoming is highly variable and
may be inﬂuenced by a number of factors. To give an
indication of the total number of bites, we have assumed that
the total number of snakebites would be two to three times
the number of envenomings. This estimate combined with
our estimate that the number of envenomings ranges from
421,000 to as high as 1,841,000 annually, we estimate
1,200,000 to 5,500,000 snakebites may occur globally per year.
Figure 6. Countries with Data on Snakebite Mortality
doi:10.1371/journal.pmed.0050218.g006
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Global Burden Region Number of Deaths per Year Range for Wider Region
Low Estimate Rate/100,000 High Estimate Rate/100,000
Asia Pacific, high income 12 0.007 18 0.010 15,385–57,636
Asia, Central 9 0.011 29 0.037
Asia, East 462 0.033 4,829 0.347
Asia, South 14,112 0.912 33,666 2.175
Asia, Southeast 790 0.134 19,094 3.245
Australasia 2 0.008 4 0.016 2–4
Caribbean 107 0.275 1,161 2.983 107–1,161
Europe, Central 6 0.005 17 0.014 48–128
Europe, Eastern 37 0.018 66 0.032
Europe, Western 5 0.001 45 0.011
Latin America, Andean 243 0.479 533 1.050 540–2,298
Latin America, Central 193 0.087 1,461 0.661
Latin America, Southern 4 0.007 5 0.008
Latin America, Tropical 100 0.051 299 0.151
North Africa/Middle East 43 0.010 78 0.018 43–78
North America, high income 5 0.001 7 0.002 5–7
Oceania 227 2.434 516 5.533 227–516
Sub-Saharan Africa, Central 256 0.286 3,083 3.441 3,529–32,117
Sub-Saharan Africa, East 1,397 0.422 10,014 3.026
Sub-Saharan Africa, Southern 286 0.414 366 0.530
Sub-Saharan Africa, West 1,590 0.504 18,654 5.909
Total 19,886 0.297 93,945 1.403 19,886–93,945
doi:10.1371/journal.pmed.0050218.t002
Figure 7. Regional Estimates of Deaths Due to Snakebite (Low Estimate)
doi:10.1371/journal.pmed.0050218.g007
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We estimate that at least 421,000 envenomings and 20,000
deaths occur worldwide from snakebite annually. These
ﬁgures may be as high as 1,841,000 envenomings and 94,000
deaths. On the basis of the estimation that the total number
of snakebites is two to three times the number of envenom-
ings, we estimate that 1,200,000–5,500,000 snakebites may
occur globally. The vast majority of the estimated burden of
snakebite is in South and Southeast Asia, sub-Saharan Africa,
and Central and South America, as identiﬁed in previous
estimates of the global burden. Despite accounting for nearly
one-fourth of the global snakebite incidence, mortality due to
snakebite is relatively lower in Central and South America
when compared to other high incidence regions. Mortality
may be lower because of better snakebite management
systems, including the development of locally effective
antivenoms, in many Latin American countries. The lower
estimates of snakebite incidence in sub-Saharan Africa are
probably a reﬂection of under-reporting from many parts of
this region; we found it particularly difﬁcult to ﬁnd reliable
data for this region, especially for East Africa. India, with its
population of over a billion people, accounted for the highest
estimated number of bites and deaths for a single country.
The most often quoted currently available estimates of the
global burden of snakebite [3,4] are subject to the major
limitation that the methodology of estimation is not given
and so cannot be reproduced. The formalization of methods
for the assessment of disease burden provides a framework
for standardized methodology [81]. In an attempt to provide a
more contemporary and accurate picture of the global
problem, we developed and applied a method to obtain an
estimate of the disease burden due to snakebite. Our global
estimates were based on regional estimates that were, in turn,
derived from data available for countries within a deﬁned
region.
The true global incidence of snakebite, envenomings, and
its associated mortality are difﬁcult to estimate. The over-
whelming majority of bites occur in rural areas of resource-
poor countries. Reporting and record-keeping in such
situations are generally poor. Snakebite varies seasonally
and geographically within countries; i.e., high incidences are
reported during agricultural activity [88]. Many estimates
from these countries are based on hospital returns or
incomplete central databases, and are bound to be under-
estimates, because many victims do not seek hospital treat-
ment and prefer traditional remedies [5]. Some may die at
home, with their deaths unrecorded [8]. Studies from rural
Nigeria and Kenya have reported that only 8.5% and 27% of
snakebite victims, respectively, sought hospital treatment
[7,89]. This situation may be common to many middle- and
low-income countries where health-seeking behaviour, health
beliefs, and access to health care are not optimal. Thus, most
of the available data on snakebite should be regarded as
underestimates.
Conversely, many of the few published community surveys
of snakebite have been performed in areas where the
problem is endemic and perhaps a major public health
problem, and incidence and mortality ﬁgures then extrapo-
lated to represent the entire country or region; this would
lead to an overestimation of the burden. To circumvent this
problem we applied the higher rates identiﬁed for a
particular country only to the rural population of that
country if the rates were reported at subnational level. This
would have resulted in considerable underestimation, be-
cause some of the published subnational studies have
reportedly been conducted in regions where snakebite is
not considered a high priority public health problem
[59,60,90,91]. It is for these reasons, and because the paucity
of data prevented more precise estimations, that we decided
to present our estimates as a range by calculating both high
and low estimates of snakebites and related mortality.
The most important issue we faced was the paucity of good-
quality published data, particularly from nationwide com-
munity-based studies. Despite this deﬁciency, we have given
priority to national estimates derived from the national
health systems and related services over rates available from
subnational studies to try to avoid overestimation of national
incidence or mortality rates. Data generated from hospital-
based studies were used in a few instances where no other
data were available, provided that the catchment population
was known.
We considered only data reported after 1985 to make the
estimates as current as possible. More than 70% of the data
that were utilised in arriving at the estimates were, in fact,
reported after 1995. Most regions lacked either population-
based studies or surveillance systems that might measure
snakebite incidence at the population level. In some cases,
many countries in a region lacked data. For example, data
were available for only one country in eastern sub-Saharan
Africa, where snakebite is known to be an important public
health problem. Population-based studies of incidence and
mortality are urgently needed to describe the epidemiology
of snakebite in these areas. In some countries that encompass
large geographical areas and have large populations such as
India, China, Indonesia, and Russia, country estimates had to
be calculated on the basis of single or few regional incidence
or mortality ﬁgures. This also means that relatively small
changes in the incidence rates could lead to considerable
differences in the estimation of the total burden in terms of
the number of envenomings and deaths. The proportion of
the population that is rural, and therefore exposed to the risk
of snakebites, can also considerably affect estimates for these
countries.
On the rare occasions where multiple studies were
reported for the same country, we selected the most
conservative incidence and mortality rates for our low
estimates. We followed this principle when extrapolating
data for countries within a region. That is, where no data
were available for a country in which bites were likely to
occur, we selected the most conservative rate available from a
country within the region as the rate for the country without
data [92]. This was done to avoid bias toward overestimation
of the incidence and mortality in the region where the study
was conducted. This is especially relevant for countries such
as China, India, and Indonesia which have very large
populations. When calculating our high estimate we used
only the higher ﬁgures of incidence to calculate burden for
the rural population of a given country (where snakebites are
commoner) and considered the lowest incidence ﬁgures when
calculating the burden in the urban population in that
country. Thus, even our high estimates could be considered
conservative.
Most previous estimates of snakebite morbidity and
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done in such high incidence areas within regions or
countries, and extrapolated to whole countries and regions.
Our approach minimised this effect, although in some
regions, such as the Caribbean, lack of data still meant that
we were forced to use very high rates in our calculations of
the high estimate. These methodological differences may
have played a substantial role in accounting for the differ-
ences between the previous estimates and our low estimate
(Table 3). The case for this is further strengthened by the fact
that those estimates are closer to our high estimate. However,
this is difﬁcult to assess given that a clear methodology is not
available for any of the previous estimates.
Another plausible reason is that we used very recent
incidence and mortality data from India and Pakistan that are
considerably lower than previous estimates. Our estimate of
about 81,000 envenomings and nearly 11,000 deaths due to
snakebite in India is much lower than the 200,000 bites and
up to 50,000 deaths quoted in previous estimates [63]. Given
the population of over one billion in India, this had a
substantial effect on our global estimates. The ﬁgures we
report from India are based on health insurance schemes
operated by many state governments such as the ‘‘Kisan
Jeevan Kalyan Yojana’’ (Ian Simpson, personal communica-
tion). These schemes compensate the farming community for
a variety of accidents, including snakebite. The level of
compensation is substantial, ranging from US$250 to
US$1,250. We feel that these ﬁgures may therefore be a more
reliable estimate than hospital records, because the victim’s
family has an incentive to report the deaths due to snakebites,
reducing the assumed impact of unreported deaths. It is
possible that unexplained deaths are attributed to snakebite,
but victims are examined and mortality certiﬁed by a doctor
as being due to snakebite.
Estimation of the total number of snakebites (both with
and without envenoming) is difﬁcult because of the scarcity
of literature that differentiates the two and variation in the
distribution of venomous snakes in the regions; few com-
munity-based studies address this. The true burden of
snakebites may not be reﬂected in hospital data, because a
considerable proportion of people with asymptomatic bites
may not seek treatment at hospitals; in some settings,
snakebite victims may preferentially attend traditional
healers. It was also not possible to ascertain whether ‘‘all
bites,’’ especially in community surveys, included bites of
nonvenomous snakes and dry bites of venomous snakes.
These non-envenoming bites would arguably not contribute
much to the burden of disease, although the opportunity cost
of the bite may affect the victims and the households
adversely. We estimated the total number of snakebites using
data on the proportion of snakebites with envenoming from
studies in different parts of the world. The proportion
envenomed varied considerably, most probably because of
both the effects of different snake species and variation in
methodology. This heterogeneity means that we have only a
crude estimate of the total number of snakebites. Our main
focus was to estimate snakebite envenoming, as it is
envenoming that causes most of the burden due to snakebite:
requirement for antivenom, hospital and intensive care unit
care, and surgery; complications; permanent sequelae; and
even death.
The WHO mortality database was the main source of
information used for estimation of the mortality due to
snakebite, providing nearly 70% of the data used. The
Table 3. Comparison between the Current and Previous Estimates of Snakebite Envenomings and Deaths















Australasia 1,460–5,895 3,000 229–520 10 200
Oceania










North America, high income 2,683–3,858 6,500 5–7 No separate data 15
North Africa/Middle East 3,017–80,191 15,000 43–78 No separate data 100
Sub-Saharan Africa, Central 18,176–47,820 500,000 3,529–32,117 400–1,000
3 20,000
Sub- Saharan Africa, East 42,834–74,823
Sub-Saharan Africa, Southern 1,613–2,296
Sub-Saharan Africa, West 27,999–294,700
Total 420,549–1,841,158 2,682,500 19,886–93,945 30,000–40,000
1 125,345
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was assessed on the basis of two criteria: the HDI and the
coverage of vital registration of deaths. Only code X20 of
ICD10 was considered snakebite to minimise inclusion of
deaths caused by other venomous animals. Code X20 does not
differentiate between deaths due to snakes and lizards.
However, lizard bites, unlike venomous snakebites, are not
known to be fatal; in fact, in the last 50 y only a few cases of
envenoming and no deaths have been reported as due to
lizard bites. Thus, from an epidemiological point of view
lizard bites are legible and have no public health implications.
In any estimation, assumptions have to be made and the
robustness and validity of the estimate depends on how well
the assumptions are met. The assumptions we made included
considering a country as free of snakebites (and associated
mortality) if there was no literature (published or unpub-
lished) indicating the occurrence of snakebite since 1985, and
assuming that the mortality data reported to the WHO
mortality database to be accurate and representative of the
national data for countries with a high HDI and a high vital
registration coverage of deaths. We did not make any
adjustments to arrive at the ﬁnal estimate of deaths for
countries with less than 100% vital registration coverage to
prevent an apparent unrealistic precision to the estimate.
The most recent incidence or mortality rate reported after
1985 was assumed to be the current rate for a country.
We estimated the numbers of snakebites and deaths only.
No reliable data were available on the long-term physical and
psychological consequences of surviving snakebite, but as
most snakebite victims are in the economically productive
age group, the economic impact of disability is likely to be
high. Although the socioeconomic burden of snakebite
cannot be stressed strongly enough, in this study we did not
attempt to quantify this burden. Global health resource
allocation is often based on DALYs (disability-adjusted life-
years), and other socioeconomic markers rather than on the
number of patients and deaths, despite the limitations of each
of these measures of burden. Future assessments of the
burden of snakebite will draw greater attention to the
problem, which in turn will help win resources to tackle this
neglected issue.
In conclusion, data from several new sources and the
development and application of a scientiﬁcally robust
method that can be replicated has enabled us to generate a
revised estimate of the global disease burden due to snake-
bite, although the inadequacy of available data and the
consequent need to rely upon extrapolation mean that this
estimate is still far from perfect. The burden is considerable,
especially in South and Southeast Asia, sub-Saharan Africa,
and Central and South America. Given the high burden, the
paucity of reliable snakebite data, particularly in some of
these areas, is both surprising and worrying. The fact that
snakebite varies geographically and seasonally, that it is
mainly a rural tropical phenomenon where reporting and
record keeping is poor, and that health-seeking behaviour is
diverse with traditional treatments being sometimes pre-
ferred to Western medicine, all contribute to the difﬁculties
faced when studying its epidemiology.
To address this problem, population-based studies of
incidence and mortality in countries that appear to have
the highest case load and mortality rates are urgently
required to clarify the situation. The quality of reporting
and recordkeeping on morbidity and mortality due to
snakebite in health facilities should be optimised. Data
sources should include traditional medical practitioners and
rural health workers, because high morbidity and mortality
due to snakebite can be encountered in geographically
isolated communities [9]. Accurate data on the epidemiology
of snakebite, globally, will facilitate prioritisation of scarce
health care resources for prevention and treatment of this
neglected health problem.
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Editors’ Summary
Background. Of the 3,000 or so snake species that exist in the world,
about 600 are venomous. Venomous snakes—which exist on every
continent except Antarctica—immobilize their prey by injecting modi-
fied saliva (venom) that contains toxins into their prey’s tissues through
their fangs—specialized, hollow teeth. Snakes also use their venoms for
self defense and will bite people who threaten, startle or provoke them.
Snakebites caused by the families Viperidae (for example, pit vipers) and
Elapidae (for example, kraits and cobras) are particularly dangerous to
people. The potentially fatal effects of being ‘‘envenomed’’ (having
venom injected) by these snakes include widespread bleeding, muscle
paralysis, and tissue destruction (necrosis) around the bite site. Bites from
these snakes can also cause permanent disability. For example, snakebite
victims, who tend to be young and male, may have to have a limb
amputated because of necrosis. The best treatment for any snakebite is
to get the victim to a hospital as soon as possible where antivenoms
(mixtures of antibodies that neutralize venoms) can be given.
Why Was This Study Done? Although snakebites occur throughout the
world, envenoming snakebites are thought to pose a particularly
important yet largely neglected threat to public health. This is especially
true in rural areas of tropical and subtropical countries where snakebites
are common but where there is limited access to health care and to
antivenoms. The true magnitude of the public-health threat posed by
snakebites in these countries (and elsewhere in the world) is unknown,
which makes it hard for public-health officials to optimize the prevention
and treatment of snakebites in their respective countries. In this study,
therefore, the researchers develop and apply a new method to estimate
the global burden of snakebite.
What Did the Researchers Do and Find? The researchers systematically
searched the scientific literature for publications on snakebites and
deaths from snakebites and extracted data on snakebite deaths in
individual countries from the World Health Organization (WHO) mortality
database. They also contacted Ministries of Health, National Poison
Centers, and snakebite experts for unpublished information (‘‘grey’’
literature) on snakebites. Together, these three approaches provided
data on the number of snakebite envenomings and deaths for 135 and
162 countries, respectively. The researchers then grouped the 227
countries of the world into 21 geographical regions, each of which
contained countries with similar population characteristics, and used the
results of studies done in individual countries within each region to
estimate the numbers of snakebite envenomings and deaths for each
region. Finally, they added up these estimates to obtain an estimate of
the global burden of snakebite. Using this method, the researchers
estimate that, worldwide, at least 421,000 envenomings and 20,000
deaths from snakebite occur every year; the actual numbers, they
suggest, could be as high as 1.8 million envenomings and 94,000 deaths.
Their estimates also indicate that the highest burden of snakebite
envenomings and death occurs in South and Southeast Asia and in sub-
Saharan Africa, and that India is the country with the highest annual
number of envenomings (81,000) and deaths (nearly 11,000).
What Do These Findings Mean? These findings indicate that snakebites
cause considerable illness and death around the world. Because of the
careful methods used by the researchers, their global estimates of
snakebite envenomings and deaths are probably more accurate than
previous estimates. However, because the researchers had to make many
assumptions in their calculations and because there are so few reliable
data on the numbers of snakebites and deaths from the rural tropics, the
true regional and global numbers of these events may differ substantially
from the estimates presented here. In particular, the regional estimates
for eastern sub-Saharan Africa, a region where snakebites are very
common and where antivenoms are particularly hard to obtain, are likely
to be inaccurate because they are based on a single study. The
researchers, therefore, call for more studies on snakebite envenoming
and deaths to be done to provide the information needed to deal
effectively with this neglected public-health problem.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050218.
  This study is further discussed in a PLoS Medicine Perspective by
Chippaux
  The MedlinePlus Medical Encyclopedia has a page on snakebites (in
English and Spanish)
  The UK National Health Service Direct health encyclopedia has
detailed information about all aspects of snakebites
  Wikipedia has pages on venomous snakes and on snakebites (note:
Wikipedia is a free online encyclopedia that anyone can edit; available
in several languages)
  The World Health Organization provides information about
antivenoms and about efforts to increase access to antivenoms in
developing countries (available in several languages)
  A previous article in PLoS Medicine also discusses the neglected
problem of snakebite envenoming: Gutie ´rrez JM, Theakston RDG,
Warrell DA (2006) Confronting the Neglected Problem of Snake Bite
Envenoming: The Need for a Global Partnership. PLoS Med 3(6): e150
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